Epigenetic Mechanism Analysis in Stroke

Stroke is a multifactorial disease influenced by genetic, epigenetic, and environmental factors. However, the mechanisms by which the genome is involved in the disease remain unclear. Epigenetics refers to heritable and modifiable processes that regulate gene expression without altering the DNA sequence. Recent studies using cell lines and animal models have provided clear evidence that epigenetic risk factors play a key role in the development of stroke, including complex dynamic processes that regulate gene expression, cellular damage response, motor function, and cognitive performance after stroke. Because epigenetic modifications are reversible processes, they may serve as markers of stroke progression, biomarkers for disease diagnosis, and the development of new targets for therapeutic intervention.

Fig. 1. Epigenetic risk factors play a key role in the development of stroke.Fig. 1. Epigenetic signatures controlling key post-stroke pathological processes. (Morris-Blanco et al., 2022)

Our Services for Analyzing Epigenetic Mechanisms in Stroke

By leveraging our expertise in epigenetics and stroke, Ace Therapeutics help clients study the impact of epigenetic modifications on the pathogenesis of stroke, and discover new targets and biomarkers for stroke. We have extensive experience in providing analysis services for the following mechanisms:

  • DNA Methylation
  • We provide animal models of stroke and in vitro models induced by oxygen-glucose deprivation (OGD) to study the role of promoter DNA methylation in stroke. We perform DNA methylation analysis using whole genome sequencing to identify differentially methylated regions such as DNMT, TIMP2, NKCC1, and THBS.

  • Histone Modification
  • We use advanced technology to perform comprehensive histone modification analysis in animal models of stroke. By mapping the distribution and abundance of specific histone modifications (e.g., acetylation and methylation marks), we can identify key genes and pathways regulated by histone modifications, such as H3 and H4.

  • Long Non-coding RNA (lncRNA)

Our advanced RNA sequencing and bioinformatics analysis allow us to comprehensively analyze the expression profile of non-coding RNAs in stroke. By identifying major stroke-sensitive lncRNAs involved in epigenetic regulation (e.g., FosDT, HOTAIR, H19, GAS5, MEG3, and XIST), we provide valuable data for potential therapeutic targets and diagnostic biomarkers for stroke.

Our Methods

  • We can comprehensively assess the changes in epigenetic regulation of DNA methylation, histone modification and non-coding RNA after stroke.
  • We utilize high-throughput screening technologies (ChIP-seq, ATAC-seq, RNA-seq, etc.) to help discover stroke-related epigenetic biomarkers and targets.
  • We employ sophisticated algorithms and computational tools to process, integrate, and interpret the vast amount of information obtained from epigenetic analyses.
  • We utilize molecular biology and cellular assays to validate the function of target.
  • We help clients design and synthesize small molecule inhibitors or activators of epigenetic enzymes.

Ace Therapeutics aims to help clients develop novel biomarkers for stroke diagnosis and prognosis, as well as new targets for therapeutic intervention by analyzing epigenetic mechanisms in stroke. Through our comprehensive analysis services, multidisciplinary approach, and state-of-the-art facilities, we strive to be your trusted partner. Contact us to advance your stroke program!

  1. Morris-Blanco, et al. (2022). Epigenetic mechanisms and potential therapeutic targets in stroke. Journal of Cerebral Blood Flow & Metabolism, 42(11), 2000-2016.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket